drugset

drugset / Trial / NCT02533570

Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus

NCT02533570 ↗

Phase 2 Terminated 20 enrolled Seagen Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of brentuximab vedotin in adults with active systemic lupus erythematosus (SLE).

Timeline

Start: 2015-07
Primary completion: 2017-06-05
Completion: 2017-06-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Brentuximab Vedotin	Monoclonal antibody	—	—

Indications